Jacobs Levy Equity Management
BLPH

Jacobs Levy Equity Management’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

Jacobs Levy Equity Management’s Portfolio BLPH Stock Details BLPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-2,119
Closed -$78K – 1273
2016
Q1 		$78K Buy
+2,119
New +$78.6K ﹤0.01% 1050

Other funds holding BLPH

NMVA
New Mountain Vantage Advisers New York $4.33B AUM 35.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
GA
Geneva Advisors Chicago, Illinois $5.81B AUM 23.71% 1-Year Est. Return

Jacobs Levy Equity Management's BLPH Position: Q2 2016 in Review

Jacobs Levy Equity Management sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q2 2016, closing a stake of 2,119 shares — an estimated $78K sold.

Jacobs Levy Equity Management first reported a position in BLPH in Q1 2016 and held it in 1 quarter. The position peaked at $78K in Q1 2016. 17 funds tracked by Wall St. Rank hold BLPH as of Q2 2016.

  • Jacobs Levy Equity Management reported no remaining Bellerophon Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 2,119 Bellerophon Therapeutics, Inc. shares in Q2 2016, an estimated $78K.
  • Jacobs Levy Equity Management first reported a position in Bellerophon Therapeutics, Inc. in Q1 2016 and held it in 1 quarter.
  • Jacobs Levy Equity Management's Bellerophon Therapeutics, Inc. position peaked at $78K in Q1 2016.
  • 17 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q2 2016.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2016, filed 15 Aug 2016.